APT Pharmaceuticals
www.aptbio.comAPT Pharmaceuticals is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection and is preparing for commercialization of the product in the US and Europe.
Read more
APT Pharmaceuticals is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection and is preparing for commercialization of the product in the US and Europe.
Read more
Country
State
California
City (Headquarters)
Burlingame
Industry
Employees
11-50
Founded
2005
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Accounting Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(5)
We'll help you understand if Lusha can solve your business needs.
